 |
Forty Seven
Last updated: April 19, 2024
Irving L. Weissman, founder
USA | Funding: $156M (+)
Website: https://www.fortyseven.io/
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
Website: https://www.fortyseven.io/
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
